false 0001022899 Protagenic Therapeutics, Inc.new 0001022899 2024-11-19 2024-11-19 0001022899 dei:FormerAddressMember 2024-11-19 2024-11-19 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockMember 2024-11-19 2024-11-19 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockWarrantsMember 2024-11-19 2024-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): November 19, 2024

 

PROTAGENIC THERAPEUTICS, INC.

 

(Exact name of Company as specified in its charter)

 

Delaware   001-12555   06-1390025

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

149 Fifth Avenue, Suite 500, New York, NY   10010
(Address of principal executive offices)   (Zip Code)

 

212-994-8200

 

(Company’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         
Protagenic Therapeutics, Inc. Common Stock   PTIX   Nasdaq
Protagenic Therapeutics, Inc. Common Stock Warrants   PTIXW   Nasdaq

 

 

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

As previously disclosed, on May 22, 2024, the Nasdaq Listing Qualifications department (“Nasdaq”) notified Protagenic Therapeutics, Inc. (the “Company”, “we” and “us”) that we did not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5550(b)(1) (the “Rule”).

 

Nasdaq provided the Company until July 8, 2024 to submit to Nasdaq a plan to regain compliance. We submitted the plan to regain compliance in a timely manner, and, Nasdaq advised the Company that it had determined to grant the Company an extension to regain compliance with the Rule.

 

The Company was unable to regain compliance with the Rule prior to the end of the plan period (November 18, 2024). As a result, on November 19, 2024, the Company received a delist determination letter from Nasdaq advising the Company that Nasdaq had determined that the Company did not meet the terms of the extension. As a result, unless the Company requests an appeal of Nasdaq’s determination, trading of the Company’s common stock will be suspended at the opening of business on November 29, 2024, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s common stock from listing and registration on Nasdaq.

 

The Company may submit a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request is expected to stay any delisting action by Nasdaq at least until the hearing process concludes and any extension granted by the Panel expires.

 

Notwithstanding the foregoing, there can be no assurance that the Panel will grant the Company’s request or an additional extension period, or that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PROTAGENIC THERAPEUTICS, INC.
     
Date: November 22, 2024 By: /s/ Alexander K. Arrow
  Name: Alexander K. Arrow
  Title: Chief Financial Officer

 

3

 

v3.24.3
Cover
Nov. 19, 2024
Entity Addresses [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 19, 2024
Entity File Number 001-12555
Entity Registrant Name Protagenic Therapeutics, Inc.new
Entity Central Index Key 0001022899
Entity Tax Identification Number 06-1390025
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 149 Fifth Avenue
Entity Address, Address Line Two Suite 500
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10010
City Area Code 212-994-8200
Local Phone Number 994-8200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Protagenic Therapeutics, Inc. Common Stock  
Entity Addresses [Line Items]  
Title of 12(b) Security Protagenic Therapeutics, Inc. Common Stock
Trading Symbol PTIX
Security Exchange Name NASDAQ
Protagenic Therapeutics, Inc. Common Stock Warrants  
Entity Addresses [Line Items]  
Title of 12(b) Security Protagenic Therapeutics, Inc. Common Stock Warrants
Trading Symbol PTIXW
Security Exchange Name NASDAQ
Former Address [Member]  
Entity Addresses [Line Items]  
City Area Code 212
Protagenic Therapeutics (NASDAQ:PTIXW)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Protagenic Therapeutics Charts.
Protagenic Therapeutics (NASDAQ:PTIXW)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Protagenic Therapeutics Charts.